CD274 and neoplasm: Responses were seen in patients with RCC previously refractory to ICI therapy and in a patient with late-line, PD-L1–negative and microsatellite stable CCA—a tumor type poorly responsive to ICI monotherapy (e.g., pembrolizumab ORR of 2.9% in patients with PD-L1 combined positive score ≤1 treated in the KEYNOTE-158 trial; refs. 28–31).